The immunomodulatory activity of different DHAs on additional CTAs expression (i.e., MAGE-A2, -A4, -A10, GAGE1-2, SSX1-2, and SSX1-5) was investigated also by RT-PCR analysis in 14 melanoma and 10 hematological cancer cell lines treated with 1 μM guadecitabine, DAC or AZA. This evidence concerns the gene MAGEA2 and hematopoietic and lymphoid cell neoplasm.